Tag Archives: Ritu Baral

Analysts Offer Insights on Healthcare Companies: Global Blood Therapeutics (NASDAQ: GBT) and Acceleron Pharma (NASDAQ: XLRN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Global Blood Therapeutics (GBT – Research Report) and Acceleron Pharma (XLRN – Research Report) with bullish sentiments. Global Blood Therapeutics (GBT) Cowen

Cowen & Co. Thinks Aptinyx Inc’s Stock is Going to Recover

In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Aptinyx Inc (APTX – Research Report). The company’s shares opened today at $3.47, close to its 52-week low of $2.88. According to TipRanks.com, Baral

Milestone Pharmaceuticals Inc (MIST) Has a New Rating from Cowen & Co.

In a report released today, Ritu Baral from Cowen & Co. initiated coverage with a Buy rating on Milestone Pharmaceuticals Inc (MIST – Research Report) and a price target of $32. The company’s shares closed on Friday at $20.70. According

NGM Biopharmaceuticals Inc (NGM) Receives a Buy from Cowen & Co.

Cowen & Co. analyst Ritu Baral maintained a Buy rating on NGM Biopharmaceuticals Inc (NGM – Research Report) today and set a price target of $25. The company’s shares closed on Friday at $13.30. According to TipRanks.com, Baral is a

Avrobio Inc (AVRO) Receives a Rating Update from a Top Analyst

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Avrobio Inc (AVRO – Research Report) yesterday. The company’s shares closed yesterday at $19.16. According to TipRanks.com, Baral is a top 100 analyst with an average return of 27.3%

Ovid Therapeutics Inc (OVID) Receives a Buy from Cowen & Co.

In a report released yesterday, Ritu Baral from Cowen & Co. maintained a Buy rating on Ovid Therapeutics Inc (OVID – Research Report). The company’s shares closed on Friday at $1.71, close to its 52-week low of $1.64. According to